



Attorney Docket # 4271-29P/CPA

RECEIVED  
I-05  
11

AUG 14 2002

TECH CENTER 1600/2900

Patent

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**COPY OF PAPERS  
ORIGINALLY FILED**

In re Application of

Thomas STRÜNGMANN et al.

Serial No.: 09/674,800

Filed: November 06, 2000

For: Transdermal Therapeutic System for the  
Administration of Candesartan


Examiner: S. Tran  
Group Art: 1615

I hereby certify that this correspondence is being  
deposited with the United States Postal Service with  
sufficient postage as first class mail in an envelope  
addressed to: Assistant Commissioner for Patents,  
Washington, D.C. 20231, on

August 7, 2002  
(Date of Deposit)

Vincent M. Fazzari

Name of applicant, assignee or Registered Representative



Signature

August 7, 2002

Date of Signature

Assistant Commissioner for Patents  
Washington, DC 20231

**INFORMATION DISCLOSURE STATEMENT**

SIR:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO 1449. Copies of the listed documents are also enclosed.

Also enclosed is a copy of a German Search Report issued in the corresponding foreign application.

BEST AVAILABLE COPY

This information is being submitted prior to the issuance of a final rejection or Notice of Allowance.

DE 43 41 444 A1 was cited for technological background. U.S. Patent No. 5,770,220 claims priority from that document.

EP 459 136 B1 claims candesartan and candesartancilexetil. X-ray powder data for candesartancilexetil. The compounds can be administered orally, parenterally,... .topically (e.g. emulsions, suspensions,... ) (page 6, lines 25-50). The only examples are for capsules, tablets and injections. There is no description or example for the transdermal administration of candesartan.

U.S. Patent No. 4,898,732 relates to implants comprising antagonists of the renin-angiotensin system to inhibit tumor growth.


It is respectfully requested that the above information be considered by the Examiner and that the copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.

In accordance with 37 C.F.R §§1.97(g) and (h), the filing of this Information Disclosure Statement should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserve(s) the right to prove that the date of publication is in fact different.

If any fees or charges are deemed required at this time in connection with the application, the same may be charged to our Patent and Trademark Office Deposit Account No. 03-2412.

Respectfully submitted,  
COHEN, PONTANI, LIEBERMAN & PAVANE

By:

  
\_\_\_\_\_  
Vincent M. Fazzari, Reg. No. 26,879  
551 Fifth Avenue, Suite 1210  
New York, New York 10176  
(212) 687-2770

Dated: August 7, 2002

BEST AVAILABLE COPY